June is Alzheimer’s & Brain Awareness Month, an annual observance dedicated to raising awareness of Alzheimer disease (AD), related dementias, and the importance of maintaining brain health across the lifespan. Established by the Alzheimer’s Association in 2014, the campaign highlights the growing burden of AD while promoting education on risk reduction, early detection, diagnosis, and advances in research and treatment.

Currently, more than 7 million Americans aged 65 years and older are living with Alzheimer dementia, a number projected to rise as the population ages. For clinicians, researchers, patients, and caregivers, Alzheimer’s & Brain Awareness Month serves as an opportunity to emphasize the importance of timely diagnosis, comprehensive care, and continued investment in therapies aimed at slowing disease progression and improving quality of life.

While increased awareness and earlier diagnosis remain critical priorities, the therapeutic landscape is also undergoing rapid transformation. Following the approvals of amyloid-targeting monoclonal antibodies, the focus of drug development has expanded beyond a singular emphasis on amyloid pathology. According to the 2026 Alzheimer disease drug development pipeline, 158 agents are currently being evaluated across 192 active clinical trials, with nearly three-quarters classified as disease-modifying therapies intended to slow or prevent disease progression.

Led by Jeffrey L. Cummings, MD, ScD, director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas, the annual analysis highlights how the AD pipeline continues to reflect a broader understanding of disease biology. Although amyloid-directed approaches remain a significant component of late-stage development, investigators are increasingly pursuing therapies that target tau pathology, neuroinflammation, synaptic dysfunction, metabolism and bioenergetics, vascular mechanisms, proteostasis, and other disease-related pathways.

This expanding diversity is reflected throughout the current development landscape, with investigational therapies targeting tau pathology, neuroinflammatory signaling, metabolic dysfunction, synaptic preservation, vascular mechanisms, and other pathways implicated in AD progression. As researchers seek to address the multifactorial nature of AD, the pipeline offers insight into how future treatment strategies may extend beyond amyloid reduction alone.

To better understand the scope and evolving composition of the AD drug development landscape, NeurologyLive examined the findings of Cummings and colleagues' 2026 pipeline analysis. The following review examines key agents across the major mechanistic categories represented in the pipeline, highlighting recent clinical developments and the therapeutic strategies shaping the next generation of AD research.

Amyloid-Targeting Therapies (2 Agents)

Although the AD drug development pipeline has expanded to encompass a broader range of biological targets, amyloid-directed therapies remain a foundational component of disease-modifying treatment strategies. By targeting amyloid-β through a variety of mechanisms, including plaque clearance, inhibition of toxic oligomer formation, and modulation of amyloid processing, these agents seek to address one of the hallmark pathological features of AD.

The clinical success of anti-amyloid therapies has validated amyloid as a therapeutic target while also encouraging the development of next-generation approaches designed to improve efficacy, delivery, and patient accessibility. Among the notable investigational agents in this category are trontinemab and valiltramiprosate (ALZ-801), 2 therapies that represent distinct strategies for targeting amyloid pathology.

Trontinemab

Trontinemab, an investigational anti-amyloid monoclonal antibody developed by Roche, is designed to enhance delivery of amyloid-targeting therapy across the blood-brain barrier through the company's Brainshuttle technology. By utilizing transferrin receptor-mediated transport, the therapy aims to increase central nervous system exposure while maintaining amyloid plaque-targeting activity, representing a potential next-generation evolution of antibody-based treatment strategies.

In the analysis by Cummings and colleagues, trontinemab was identified in 2 ongoing studies, 1 of which is a phase 3 investigation. These trials are evaluating the efficacy and safety of enhanced amyloid-targeting delivery approaches in patients with early AD. As researchers continue to refine antibody-based therapies, trontinemab highlights efforts to improve therapeutic penetration into the brain while building upon the clinical foundation established by earlier anti-amyloid agents.

Valiltramiprosate (ALZ-801)

Valiltramiprosate (ALZ-801), an investigational oral small-molecule therapy developed by Alzheon, represents a distinct amyloid-targeting strategy focused on preventing the formation of toxic amyloid-β oligomers. As a prodrug of tramiprosate, the agent is designed to inhibit amyloid aggregation upstream of plaque formation, offering an alternative approach to antibody-mediated plaque clearance.

According to the analysis, valiltramiprosate was identified in 1 ongoing phase 3 study. The program is evaluating whether inhibition of amyloid-β oligomer formation can slow disease progression and influence clinical outcomes in patients with early-stage AD. As interest grows in diversifying amyloid-directed treatment strategies, valiltramiprosate remains one of the leading small-molecule programs seeking to complement or provide an alternative to monoclonal antibody approaches.

Tau-Targeting Therapies (2 Agents)

While amyloid-directed therapies have established the first disease-modifying treatment paradigm in AD, tau pathology remains closely linked to neurodegeneration, disease progression, and cognitive decline. Investigators have increasingly pursued therapeutic strategies aimed at reducing tau production, preventing tau aggregation, or limiting the spread of pathological tau throughout the brain.

The current pipeline includes approaches ranging from antisense oligonucleotides to monoclonal antibodies designed to target distinct aspects of tau biology. Among the most prominent investigational agents in this category are BIIB080 (diranersen) and etalanetug (E2814), 2 therapies seeking to further expand the disease-modifying treatment landscape beyond amyloid reduction alone.

BIIB080

BIIB080 (diranersen), an antisense oligonucleotide developed by Biogen and Ionis Pharmaceuticals, is designed to reduce tau production by targeting messenger RNA associated with the MAPT gene. As one of the most advanced tau-lowering therapies currently in development, the agent represents a leading effort to directly address tau pathology associated with neurodegeneration and clinical progression in AD.

In the analysis, BIIB080 was identified in an ongoing phase 2 study. The program is evaluating whether tau lowering through antisense oligonucleotide-mediated suppression of tau mRNA can translate into measurable changes in biomarkers and clinical outcomes.

Etalanetug

Etalanetug (E2814), an investigational monoclonal antibody developed by Eli Lilly, is designed to target pathological tau species believed to contribute to the spread of tau pathology throughout the brain. Unlike tau-lowering approaches that seek to reduce protein production, E2814 aims to interfere with the propagation of abnormal tau.

According to the analysis, E2814 is being evaluated in 2 ongoing studies, including a phase 2 and phase 3 trial, both examining the agent in combination with lecanemab. This combination approach reflects growing interest in targeting multiple pathological pathways simultaneously as researchers continue to expand beyond amyloid-focused strategies.

Metabolic / Neuroprotective Approaches (2 agents)

Beyond therapies designed to directly target hallmark AD pathologies such as amyloid-β and tau, investigators are increasingly exploring approaches aimed at improving neuronal resilience and addressing broader biological processes associated with neurodegeneration. Metabolic dysfunction, impaired cellular energy regulation, and disrupted neuronal signaling have emerged as potential contributors to cognitive decline and disease progression.

The current pipeline includes agents designed to influence metabolic pathways, enhance neuronal function, and support neuroprotective mechanisms. Among the notable investigational programs in this category are AR1001 and semaglutide.

AR1001

AR1001, an investigational oral therapy developed by AriBio, is a phosphodiesterase type 5 (PDE5) inhibitor being evaluated as a potential disease-modifying approach for Alzheimer disease. Rather than directly targeting amyloid or tau pathology, AR1001 is designed to modulate PDE5 signaling pathways involved in neuronal communication, synaptic plasticity, and cognitive processes, representing an approach focused on supporting neuronal function and resilience.

In Cummings et al., AR1001 was identified in 1 ongoing phase 3 study. The trial is evaluating whether PDE5 inhibition can influence cognitive outcomes and disease-related measures, reflecting broader efforts to explore therapeutic strategies that may preserve or restore neuronal function beyond traditional pathological targets.

Semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained interest as a potential therapeutic approach in AD due to emerging evidence linking metabolic dysfunction, impaired insulin signaling, and neurodegeneration. Originally developed for metabolic disorders, semaglutide is being investigated for potential effects on brain metabolism, neuroinflammatory pathways, and neuronal health.

In Cummings et al., semaglutide was identified in 3 ongoing studies, including 1 phase 3 trial. These investigations are evaluating whether GLP-1 receptor activation can affect cognitive decline and disease-related biomarkers in patients with AD. The inclusion of semaglutide in the AD pipeline reflects the field’s expanding focus on systemic biological processes that may contribute to neurodegeneration and cognitive impairment.

REFERENCES
1. 2026 Alzheimer's diseasefacts and figures. Alzheimer's Dement. 2026;22(4)e71345. Doi: 10.1002/alz.71345
2. Alzheimer’s Disease Drug Development Pipeline is Growing in Size, Number and Variety. Alzheimer’s Association. News Release. May 5, 2026. Accessed: June 17, 2026. https://www.alz.org/news/2026/alzheimers-disease-drug-development-pipeline-is-growing
3. Cummings JL, Zhou Y, Yang Y, et al. Alzheimer's disease drug development pipeline: 2026. Alzheimer's Dement. 2026;12:e70251. Doi: 10.1002/trc2.70251